Remdesivir approved for use in non-hospitalized patients
The Food and Drug Administration has expanded its approval for remdesivir, an antiviral drug used to treat COVID-19, to include people who are not hospitalized. Previously, the approval was limited to patients who were already hospitalized.
The expanded use was based on a study that found high-risk COVID-19 patients who were treated with remdesivir were less likely to be hospitalized than patients who got a placebo.
"Today's actions provide adults and pediatric patients, with mild-to-moderate COVID-19 who are at high risk of severe COVID-19, with a treatment option they could receive outside of a traditional inpatient hospital setting, including at skilled nursing facilities, home healthcare settings and outpatient facilities such as infusion centers," Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement Friday.
The intravenous drug, known by the brand name Veklury, is approved for use in patients as young as 12 years old who weigh at least 88 pounds.
-ABC News' Sasha Pezenik